Update on therapy of chronic immune-mediated neuropathies
Authors:
- 16 January 2021
- journal article
- review article
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (S2) , 605-614
Abstract
Chronic immune-mediated neuropathies, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), neuropathies associated with monoclonal gammopathy, and multifocal motor neuropathy (MMN), are a group of disorders deemed to be caused by an immune response against peripheral nerve antigens. Several immune therapies have been reported to be variably effective in these neuropathies including steroids, plasma exchange, and high-dose intravenous (IVIg) or subcutaneous (SCIg) immunoglobulins. These therapies are however far from being invariably effective and may be associated with a number of side effects leading to the use of immunosuppressive agents whose efficacy has not been so far confirmed in randomized trials. More recently, new biological agents, such as rituximab, have proved to be effective in patients with neuropathy associated with IgM monoclonal gammopathy and are currently tested in CIDP.Keywords
This publication has 111 references indexed in Scilit:
- Bioavailability of IgG Administered by the Subcutaneous RouteJournal of Clinical Immunology, 2013
- An open‐label trial of rituximab (Rituxan®) in multifocal motor neuropathyJournal of the Peripheral Nervous System, 2010
- Rituximab for polyneuropathy with IgM monoclonal gammopathyJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single‐blinded cross‐over trialEuropean Journal of Neurology, 2009
- Predictors of response to rituximab in patients with neuropathy and anti–myelin associated glycoprotein immunoglobulin MJournal of the Peripheral Nervous System, 2007
- Flare in Neuropathy Following Rituximab Therapy for Waldenstrom’s MacroglobulinemiaJournal of Clinical Oncology, 2006
- Rituximab therapy in monoclonal IgM-related neuropathiesLeukemia & Lymphoma, 2006
- Worsening after rituximab treatment in anti‐mag neuropathyMuscle & Nerve, 2005
- Treatment of IgM antibody associated polyneuropathies using rituximabJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Plasma-Cell Dyscrasia and Peripheral Neuropathy with a Monoclonal Antibody to Peripheral-Nerve MyelinNew England Journal of Medicine, 1980